What smart money is saying about Royalty Pharma
2 funds in our archive have pitched Royalty Pharma — most recently PM Capital Global Opportunities Fund Limited in August 2026.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Get an email when a fund writes about it
Position history
Between Q3 2025 and Q3 2026, 2 fund letters reported a position in Royalty Pharma, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 1 |
| Q2 2026 | 1 | 0 | 0 | 0 |
| Q3 2025 | 0 | 0 | 0 | 1 |
Fund activity · 2 positions
- August 2026
“One of our key healthcare positions – Royalty Pharma – delivered strong returns in FY26.”
Royalty Pharma - HoldsLatitude Global FundJune 2026
“Our most recent addition in the healthcare sector, Royalty Pharma, continues to deliver on its medium-term plan.”
Royalty Pharma
Also mentioned · 1
These funds discuss Royalty Pharma — as a competitor, benchmark or comparable — without disclosing a position in it.
- June 2026
“Importantly, the recent spin of the development assets was a taxable event. Anaptysbio CEO Dan Faga was previously an investment banker, and I suspect that this was a deliberate choice. There are no tax barriers to an acquisition. It also may be worth noting that Susannah Grey, formerly CFO of Royalty Pharma (RPRX) recently joined Anaptysbio’s board.”
Royalty Pharma
Fund coverage · 2 theses
- PM Capital Global Opportunities Fund LimitedAugust 2026
Royalty Pharma invests in drug royalties and is seen as benefiting from long-term growth in royalty funding demand.
Read the full thesis - Cooper Investors Global EndowmentSeptember 2025
Royalty Pharma generates consistent biotech and pharma IP royalties with expected pipeline growth and broader investor appeal after converting to a C-Corp.
Read the full thesis
Read every full thesis on Royalty Pharma
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→